SS Innovations Sees Full-Year Revenue Jump 105.7% to $42.5M, 103 Installations
SS Innovations’ Q4 revenue surged 79.1% to $14.5M, lifting annual sales 105.7% to $42.5M, while SSi Mantra installations climbed 81.8% to 40 in Q4 and 119.1% to 103. The company cut 2025 net loss to $12.1M and raised $18.6M in private placement for FDA 510(k) and EU CE-mark filings.
1. Fourth Quarter 2025 Results
SS Innovations posted Q4 revenue of $14.5 million, up 79.1% year-over-year, with gross profit rising 60.7% to $6.4 million despite a margin decline to 43.9%. Net loss widened to $2.5 million, while SSi Mantra installations grew 81.8% to 40 and quarterly surgeries nearly tripled to 1,828.
2. Full Year 2025 Highlights
Full-year revenue climbed 105.7% to $42.5 million, driving gross profit up 131.2% to $19.5 million and expanding margin to 46.0%. The net loss narrowed to $12.1 million, installations rose 119.1% to 103 units, the installed base reached 168 across ten countries, cumulative surgeries hit 7,885, cash totaled $3.2 million and long-term debt stood at zero.
3. Capital Raise and Regulatory Progress
In March the company closed a private placement of 5.77 million shares, raising $18.6 million before expenses—$4.00 per share from insiders and $3.00 from non-affiliates—to fund growth. Management expects FDA 510(k) clearance by mid-2026 and EU CE marking this year, while advancing new 5 mm instruments, robotic telesurgery innovations and global market expansion.